The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia: A New β-Aminobutyric Acid Agonist

Søren Korsgaard, Daniel Casey, Jes Gerlach, Ole Hetmar, Bjørn Kaldan, Leif B. Mikkelsen

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

β-Aminobutyric acid (GABA) agonists have been proposed for the treatment of tardive dyskinesia, but their therapeutic potential has been limited by side effects and toxicity. To elucidate further the role of GABA in neuroleptic-induced dyskinesias, we evaluated tetrahydroisoxazolopyridinol (THIP), a new, less toxic GABA analog and GABA receptor agonist, in both a dose-finding (single-dose) pilot study with five patients and a longer (four-week) placebo-controlled study with 13 patients. The patients were videotaped during a standardized examination; tardive dyskinesia, parkinsonian symptoms, and eye-blinking rates were rated blindly and randomly. The maximal shortterm dose of THIP was 10 to 25 mg, whereas in the longer-term study the highest daily dose ranged from 20 to 120 mg. Tardive dyskinesia was unchanged during THIP treatment, but preexisting parkinsonism increased significantly and eye-blinking rates decreased. Psychiatric symptoms showed no significant changes, although tension and depression lessened. Side effects included sedation, confusion, dizziness, vomiting, and myoclonic jerks. Although THIP is not an effective new treatment for tardive dyskinesia, more specific GABA agonists should be evaluated in future studies of this syndrome.

Original languageEnglish (US)
Pages (from-to)1017-1021
Number of pages5
JournalArchives of General Psychiatry
Volume39
Issue number9
DOIs
StatePublished - 1982

Fingerprint

Aminobutyrates
GABA Agonists
Blinking
gamma-Aminobutyric Acid
Myoclonus
Poisons
Dyskinesias
Parkinsonian Disorders
Dizziness
Therapeutics
Antipsychotic Agents
Vomiting
Psychiatry
Placebos
Tardive Dyskinesia
Dose

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia : A New β-Aminobutyric Acid Agonist. / Korsgaard, Søren; Casey, Daniel; Gerlach, Jes; Hetmar, Ole; Kaldan, Bjørn; Mikkelsen, Leif B.

In: Archives of General Psychiatry, Vol. 39, No. 9, 1982, p. 1017-1021.

Research output: Contribution to journalArticle

Korsgaard, Søren ; Casey, Daniel ; Gerlach, Jes ; Hetmar, Ole ; Kaldan, Bjørn ; Mikkelsen, Leif B. / The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia : A New β-Aminobutyric Acid Agonist. In: Archives of General Psychiatry. 1982 ; Vol. 39, No. 9. pp. 1017-1021.
@article{8d05c59e7df1445e9f0b729f9f466e29,
title = "The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia: A New β-Aminobutyric Acid Agonist",
abstract = "β-Aminobutyric acid (GABA) agonists have been proposed for the treatment of tardive dyskinesia, but their therapeutic potential has been limited by side effects and toxicity. To elucidate further the role of GABA in neuroleptic-induced dyskinesias, we evaluated tetrahydroisoxazolopyridinol (THIP), a new, less toxic GABA analog and GABA receptor agonist, in both a dose-finding (single-dose) pilot study with five patients and a longer (four-week) placebo-controlled study with 13 patients. The patients were videotaped during a standardized examination; tardive dyskinesia, parkinsonian symptoms, and eye-blinking rates were rated blindly and randomly. The maximal shortterm dose of THIP was 10 to 25 mg, whereas in the longer-term study the highest daily dose ranged from 20 to 120 mg. Tardive dyskinesia was unchanged during THIP treatment, but preexisting parkinsonism increased significantly and eye-blinking rates decreased. Psychiatric symptoms showed no significant changes, although tension and depression lessened. Side effects included sedation, confusion, dizziness, vomiting, and myoclonic jerks. Although THIP is not an effective new treatment for tardive dyskinesia, more specific GABA agonists should be evaluated in future studies of this syndrome.",
author = "S{\o}ren Korsgaard and Daniel Casey and Jes Gerlach and Ole Hetmar and Bj{\o}rn Kaldan and Mikkelsen, {Leif B.}",
year = "1982",
doi = "10.1001/archpsyc.1982.04290090021005",
language = "English (US)",
volume = "39",
pages = "1017--1021",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia

T2 - A New β-Aminobutyric Acid Agonist

AU - Korsgaard, Søren

AU - Casey, Daniel

AU - Gerlach, Jes

AU - Hetmar, Ole

AU - Kaldan, Bjørn

AU - Mikkelsen, Leif B.

PY - 1982

Y1 - 1982

N2 - β-Aminobutyric acid (GABA) agonists have been proposed for the treatment of tardive dyskinesia, but their therapeutic potential has been limited by side effects and toxicity. To elucidate further the role of GABA in neuroleptic-induced dyskinesias, we evaluated tetrahydroisoxazolopyridinol (THIP), a new, less toxic GABA analog and GABA receptor agonist, in both a dose-finding (single-dose) pilot study with five patients and a longer (four-week) placebo-controlled study with 13 patients. The patients were videotaped during a standardized examination; tardive dyskinesia, parkinsonian symptoms, and eye-blinking rates were rated blindly and randomly. The maximal shortterm dose of THIP was 10 to 25 mg, whereas in the longer-term study the highest daily dose ranged from 20 to 120 mg. Tardive dyskinesia was unchanged during THIP treatment, but preexisting parkinsonism increased significantly and eye-blinking rates decreased. Psychiatric symptoms showed no significant changes, although tension and depression lessened. Side effects included sedation, confusion, dizziness, vomiting, and myoclonic jerks. Although THIP is not an effective new treatment for tardive dyskinesia, more specific GABA agonists should be evaluated in future studies of this syndrome.

AB - β-Aminobutyric acid (GABA) agonists have been proposed for the treatment of tardive dyskinesia, but their therapeutic potential has been limited by side effects and toxicity. To elucidate further the role of GABA in neuroleptic-induced dyskinesias, we evaluated tetrahydroisoxazolopyridinol (THIP), a new, less toxic GABA analog and GABA receptor agonist, in both a dose-finding (single-dose) pilot study with five patients and a longer (four-week) placebo-controlled study with 13 patients. The patients were videotaped during a standardized examination; tardive dyskinesia, parkinsonian symptoms, and eye-blinking rates were rated blindly and randomly. The maximal shortterm dose of THIP was 10 to 25 mg, whereas in the longer-term study the highest daily dose ranged from 20 to 120 mg. Tardive dyskinesia was unchanged during THIP treatment, but preexisting parkinsonism increased significantly and eye-blinking rates decreased. Psychiatric symptoms showed no significant changes, although tension and depression lessened. Side effects included sedation, confusion, dizziness, vomiting, and myoclonic jerks. Although THIP is not an effective new treatment for tardive dyskinesia, more specific GABA agonists should be evaluated in future studies of this syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0019955279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019955279&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1982.04290090021005

DO - 10.1001/archpsyc.1982.04290090021005

M3 - Article

C2 - 6126170

AN - SCOPUS:0019955279

VL - 39

SP - 1017

EP - 1021

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 9

ER -